BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor™ System for rapid detection of Flu A+B. This is the first rapid influenza test system that incorporates a digital read out of results to receive CLIA waiver.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53615-bd-veritor-system-influenza-test-receives-510k-clearance-fda-clia-waiver
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Today, a new study from P&G Beauty & Grooming and lead investigator Nancy Etcoff, PhD., Assistant Clinical Professor at Harvard University and Associate Researcher at Massachusetts General Hospital Department of Psychiatry, confirms for the first time that using color cosmetics does, in fact, significantly alter how women are perceived by others, at first glance and over time. Results of the study, published on October 3, 2011 in PLoS ONE, show that makeup application specifically impacts judgments of attractiveness and character when viewed rapidly or for unlimited amounts of time.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52087-p-g-harvard-study-reveals-cosmetics-alter-instinctual-perception
Caralluma
Fimbriata is widely acknowledged as the MOST POWERFUL weight loss and
appetite suppressant that is completely natural and 100% side effect
free! To learn all about Caralluma and what it means for YOU CLICK http://carallumaforyou.com/ To learn about the bestselling Caralluma product CLICK http://carallumaforyou.com/caralluma-actives
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
The findings of the six-person study mark the first proof that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder. Results of the Phase I study appear in the December 10 online edition of the New England Journal of Medicine. The research is also scheduled to be presented December 11 at the 53rd annual meeting of the American Society of Hematology in San Diego.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46766-st-jude-children-s-research-hospital-gene-therapy-bleeding-disorder
Emdeon Inc., a leading provider of revenue and payment cycle management and clinical information exchange solutions, today announced the launch of Emdeon EDGE™, an integrated, technology-enabled solution that includes complete payment integrity and cost containment services designed to help detect improper healthcare claims and prevent inaccurate payments.
To view Multimedia News Release, go to http://www.multivu.com/mnr/48121-emdeon-edge-payment-integrity-cost-management
Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta’s revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55638-elekta-agility-radiation-therapy-radiotherapy-cancer-sbrt
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management and clinical information exchange solutions, today announced a collaboration with Atigeo™, a compassionate technology company that turns science into products and services for a wiser world. Together, Emdeon and Atigeo plan to explore the use of intelligent analytics layered on top of petabytes of healthcare data to improve health outcomes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59755-emdeon-and-atigeo-intelligent-analytics-for-health-outcomes-himss13
Inspired by its surrounding southwestern landscape, the Health Sciences Education Building (HSEB) at The University of Arizona College of Medicine-Phoenix is one of the most innovative construction projects in the United States utilizing predominately recycled copper. Using nearly 6,000 copper panels and more than 10,000 copper parts, this 268,000 square-foot building consists of six stories of administration and faculty offices, lecture halls, learning studios, flexible classrooms, clinical suites, gross anatomy facilities, laboratories and conference rooms.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61608-copper-development-green-sustainability-video-case-study-credit-architects
New research has revealed that the use of Antimicrobial Copper surfaces in hospital rooms can reduce the number of healthcare-acquired infections (HAIs) by 58% as compared to patients treated in Intensive Care Units with non-copper touch surfaces. In the United States, 1 out of every 20 hospital patients develops an HAI, resulting in an estimated 100,000 deaths per year. Although numerous strategies have been developed to decrease these infections, Antimicrobial Copper is the only strategy that works continuously, has been scientifically proven to be effective and doesn’t depend on human behavior, according to a recently published study in the SHEA Journal of Infection Control and Hospital Epidemiology.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61120-antimicrobial-copper-surfaces-reduce-healthcare-acquired-infections
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that subscribers to Epilog.us can now access the latest information related to Practice Management & Epilepsy at http://www.Epilog.us. Led by Dr. Aatif Husain, Director of the Clinical Neurophysiology Fellowship, Professor of Medicine, Division of Neurology, Duke University Medical Center, and Dr. John Stern, Co‐Director of the Seizure Disorder Center and Professor of Neurology at the David Geffen School of Medicine at UCLA, areas of focus include: the importance of billing code accuracy; commonly utilized billing codes in epilepsy and neurology; and epilepsy quality measures from the American Academy of Neurology (AAN).
To view Multimedia News Release, go to http://www.multivu.com/mnr/58062-upsher-smith-epilog-us-practice-management-epilepsy-resources-available
